WEST PHARMACEUTICAL SERVICES INC — Director's Dealing 2023

Mar 9, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: WEST PHARMACEUTICAL SERVICES INC (WST)
CIK: 0000105770
Period of Report: 2023-03-07

Reporting Person: Green Eric Mark (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-07	Common Stock	M	50000.00	$57.38	Acquired	135705.0865	Direct
2023-03-07	Common Stock	S	3154.00	$320.6002	Disposed	85705.0865	Direct
2023-03-07	Common Stock	S	7685.00	$321.6138	Disposed	88859.0865	Direct
2023-03-07	Common Stock	S	26753.00	$322.4874	Disposed	96544.0865	Direct
2023-03-07	Common Stock	S	5277.00	$323.3804	Disposed	123297.0865	Direct
2023-03-07	Common Stock	S	1131.00	$324.29	Disposed	128574.0865	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-07	Stock Option (Right to Buy)	$57.38	M	50000.00	Disposed	2025-04-24	Common Stock (50000.00)	Direct

Footnotes

F1: The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 9/14/2022.

F2: This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.

F3: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $320.06 to $321.05, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

F4: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $321.06 to $322.05, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

F5: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $322.07 to $323.05, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

F6: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $323.09 to $324.03, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

F7: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $324.10 to $324.55, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.

F8: This option is fully vested.